Lenovo Commits to Hiring 12,000 R&D Professionals, and Outlines Vision to Achieve Net-zero by 2050
4.4.2022 09:00:00 EEST | Business Wire | Press release
Today, at Lenovo’s annual company kick-off to mark the start of Lenovo’s financial year, Chairman and CEO, Yuanqing Yang, set out the company’s bold vision for the year ahead. This includes building on its recent commitment to double investment in Research and Development (R&D) and announcing that the Group will hire 12,000 R&D professionals around the world over the next three years, as well as setting a vision to achieve net-zero by 2050*. The intensified commitment to innovation, underpinned by Environmental, Social, Governance (ESG) commitments, comes as Lenovo continues its transformation from a devices company to a global technology powerhouse that also includes services and solutions.
Lenovo’s CEO outlined the Group’s mission for the year ahead to build new growth engines, invest in new and emerging technologies, and continue driving sustainable profitability improvements.
R&D remains a crucial priority for Lenovo in fiscal year 22/23. R&D investment will be doubled, and 12,000 new R&D professionals hired over the next three years, in addition to around 5,000 brought into the company during fiscal FY21/22, to support research across the new IT architecture of ‘Client-Edge-Cloud-Network-Intelligence’
“My vision for Lenovo’s innovation is to become one of the world’s leading ICT companies, a pioneer and enabler of intelligent transformation,” said Chairman and CEO, Yuanqing Yang. “Our investment plan will center around the 'Client-Edge-Cloud-Network-Intelligence' architecture, with a three-track approach to focus on short-, medium- and long-term payback. Our intention is to optimize between technology with quick market returns and foundational research, and between continuous improvement and breakthrough innovation.”
R&D efforts will focus around the new and emerging IT architecture. Teams will work on new product and business model innovation, incubating technologies from edge computing to technology which will help businesses capitalize on the metaverse, and emerging and disruptive innovation like next-generation AI and heterogeneous computing to help them prepare for the future. All with the intention of helping businesses of all sizes capitalize on new and emerging technologies like the metaverse.
Alongside its R&D commitments, Lenovo outlined its vision to become net-zero by 2050, and Lenovo is working with the Science Based Target Initiative to establish goals that support this vision. The company has been reporting on its ESG commitments for the past 14 years, including outlining its work and goals around climate change mitigation, the circular economy, and sustainable materials. In 2020, Lenovo exceeded its 2020 emission reduction goals a year ahead of schedule and has already established science-based targets for 2030
In addition to the net-zero vision, Yuanqing Yang further committed to positively impacting 15 million lives through philanthropic programs and partnerships by 2025. The company’s philanthropic mission provides smarter technology for all by empowering underrepresented communities with access to technology and STEM education.
Yuanqing Yang concluded: “Lenovo is much more than business growth and financial success. We are innovators who are committed to helping solve humanity’s greatest challenges. Smarter powers what’s next.”
Read more about Lenovo’s sustainability initiatives in the most recent ESG Report, including the 2030 greenhouse gas emissions reduction goals approved by the Science-Based Targets initiative.
* Lenovo is working with the Science Based Target Initiative to establish goals that support this vision.
About Lenovo
Lenovo (HKSE: 992) (ADR: LNVGY) is a US$60 billion revenue Fortune Global 500 company serving customers in 180 markets around the world. Focused on a bold vision to deliver smarter technology for all, we are developing world-changing technologies that power (through devices and infrastructure) and empower (through solutions, services, and software) millions of customers every day and together create a more inclusive, trustworthy and sustainable digital society for everyone, everywhere. To find out more visit https://www.lenovo.com and read about the latest news via our StoryHub.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220403005029/en/
Contact information
Stuart Gill, sgill@lenovo.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 13:38:00 EEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom